Literature DB >> 29571347

Salvage Pulmonary Metastasectomy for Local Relapse After Stereotactic Body Radiotherapy.

Masatsugu Hamaji1, Takamasa Mitsuyoshi2, Akihiko Yoshizawa3, Toshihiko Sato4, Yukinori Matsuo2, Toyofumi-Fengshi Chen-Yoshikawa4, Makoto Sonobe4, Takashi Mizowaki2, Hiroshi Date4.   

Abstract

Although several studies have evaluated the local control and survival outcomes in patients undergoing stereotactic body radiotherapy (SBRT) for pulmonary oligometastases, little data are available on the management of local relapse. Here, we present 3 patients who underwent lobectomy and mediastinal lymph node dissection as salvage pulmonary metastasectomy for local relapse after SBRT. The postoperative course has been uneventful for all 3 patients, with no evidence of disease at 40, 51, and 6 months from the salvage metastasectomy. Our experience suggests that salvage pulmonary metastasectomy may be associated with local control and long-term survival in carefully selected patients.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29571347     DOI: 10.1016/j.athoracsur.2017.11.003

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  3 in total

1.  Diagnostic and planned salvage pulmonary metastasectomy.

Authors:  Masatsugu Hamaji; Ryo Miyata; So Miyahara
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 0.496

Review 2.  Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy.

Authors:  Sameera S Kumar; Ronald C McGarry
Journal:  Transl Lung Cancer Res       Date:  2019-09

3.  The histologic effects of neoadjuvant stereotactic body radiation therapy (SBRT) followed by pulmonary metastasectomy-rationale and protocol design for the Post SBRT Pulmonary Metastasectomy (PSPM) trial.

Authors:  Housne Begum; Anand Swaminath; Yung Lee; Christine Fahim; Jonathan Bramson; Asghar Naqvi; Yaron Shargall; Christian Finley; Wael Hanna; John Agzarian
Journal:  Transl Cancer Res       Date:  2022-04       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.